Company Information

 

Australian Clinical Labs Limited (ASX: ACL)

Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients.

It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing.

Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.

 

Top Australian Brokers

 

REVENUE IN AUD (TTM)

674.03m

NET INCOME IN AUD

15.43m

Year on year Australian Clinical Labs Ltd’s revenues fell -29.99% from 995.60m to 697.07m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 178.24m to 35.90m, a -79.86% decrease.

 

Australian Clinical Labs Limited (ASX: ACL) Live Chart

 

Australian Clinical Labs Limited (ASX: ACL) Forecast

Based on 1 Wall Street analysts offering 12 month price targets for Australian Clinical Labs Ltd The average price target is AU$3.20 with a high forecast of AU$3.20 and a low forecast of AU$3.20. The average price target represents a 23.55% change from the last price of AU$2.59.

 

Latest ASX News

 

Australian Clinical Labs Limited (ASX: ACL) Performance

 

Australian Clinical Labs Limited (ASX: ACL) Fundamentals

 

Australian Clinical Labs Limited (ASX: ACL) Competitors

 

Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2024.

We’re giving away this valuable research for FREE.

Click below to secure your copy